Search Results - "Yazici, Y" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee

by Deshmukh, V., Hu, H., Barroga, C., Bossard, C., KC, S., Dellamary, L., Stewart, J., Chiu, K., Ibanez, M., Pedraza, M., Seo, T., Do, L., Cho, S., Cahiwat, J., Tam, B., Tambiah, J.R.S., Hood, J., Lane, N.E., Yazici, Y.
Published in Osteoarthritis and cartilage (01.01.2018)

Get full text

Journal Article

Long-term safety of methotrexate in the treatment of rheumatoid arthritis

Long-term safety of methotrexate in the treatment of rheumatoid arthritis

by Yazici, Y
Published in Clinical and experimental rheumatology (01.09.2010)

Get full text

Journal Article

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

by Yazici, Y., McAlindon, T.E., Fleischmann, R., Gibofsky, A., Lane, N.E., Kivitz, A.J., Skrepnik, N., Armas, E., Swearingen, C.J., DiFrancesco, A., Tambiah, J.R.S., Hood, J., Hochberg, M.C.
Published in Osteoarthritis and cartilage (01.10.2017)

Get full text

Journal Article

OP0108 LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDED CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OA

OP0108 LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDED CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OA

by Seo, T., Deshmukh, V., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2021)

Get full text

Journal Article

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

by Deshmukh, V., O'Green, A.L., Bossard, C., Seo, T., Lamangan, L., Ibanez, M., Ghias, A., Lai, C., Do, L., Cho, S., Cahiwat, J., Chiu, K., Pedraza, M., Anderson, S., Harris, R., Dellamary, L., KC, S., Barroga, C., Melchior, B., Tam, B., Kennedy, S., Tambiah, J., Hood, J., Yazici, Y.
Published in Osteoarthritis and cartilage (01.09.2019)

Get full text

Journal Article

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

by Yazici, Y., McAlindon, T.E., Gibofsky, A., Lane, N.E., Lattermann, C., Skrepnik, N., Swearingen, C.J., Simsek, I., Ghandehari, H., DiFrancesco, A., Gibbs, J., Tambiah, J.R.S., Hochberg, M.C.
Published in Osteoarthritis and cartilage (01.05.2021)

Get full text

Journal Article

THU0522 Experimental tendinopathy treatment with sm04755, a topical small molecule inhibitor of the wnt pathway

THU0522 Experimental tendinopathy treatment with sm04755, a topical small molecule inhibitor of the wnt pathway

by Deshmukh, V., Seo, T., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

THU0046 Small molecule inhibitor of the wnt pathway (SM04755) as a potential topical treatment for psoriasis

THU0046 Small molecule inhibitor of the wnt pathway (SM04755) as a potential topical treatment for psoriasis

by Deshmukh, V., Pedraza, M., Lamangan, L., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

FRI0552 Sm04690, a wnt pathway inhibitor: anti-inflammatory and cartilage protective effects in preclinical oa models

FRI0552 Sm04690, a wnt pathway inhibitor: anti-inflammatory and cartilage protective effects in preclinical oa models

by Deshmukh, V., Seo, T., Swearingen, C., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

AB0440 Ethnic minorities experience infrequent biologic switch despite active rheumatoid arthritis disease

AB0440 Ethnic minorities experience infrequent biologic switch despite active rheumatoid arthritis disease

by Kerr, G., Swearingen, C., Hochberg, S., Ude, J., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

FRI0495 BehÇet’s syndrome in new york and amsterdam: evolution from probable behÇet’s to isg criteria positive behÇet’s

FRI0495 BehÇet’s syndrome in new york and amsterdam: evolution from probable behÇet’s to isg criteria positive behÇet’s

by Kerstens, F., Turkstra, F., Swearingen, C.J., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

POS0828 CONSISTENT EFFICACY WITH APREMILAST IN MEN AND WOMEN TO TREAT ORAL ULCERS ASSOCIATED WITH BEHÇET’S SYNDROME: PHASE 3 RELIEF STUDY RESULTS

POS0828 CONSISTENT EFFICACY WITH APREMILAST IN MEN AND WOMEN TO TREAT ORAL ULCERS ASSOCIATED WITH BEHÇET’S SYNDROME: PHASE 3 RELIEF STUDY RESULTS

by Hatemi, G., Mahr, A., Takeno, M., Kim, D., Melikoglu, M., Cheng, S., Richter, S., Jardon, S., Paris, M., Chen, M., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2021)

Get full text

Journal Article

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures

by Pincus, T., Bergman, M. J., Yazici, Y., Hines, P., Raghupathi, K., Maclean, R.
Published in Rheumatology (Oxford, England) (01.03.2008)

Get full text

Journal Article

FRI0255 Patients Treated for Behcet's Syndrome in the US Have Higher Disease Activity Scores at Presentation if they Fulfill Diagnostic Criteria and if they are Females

FRI0255 Patients Treated for Behcet's Syndrome in the US Have Higher Disease Activity Scores at Presentation if they Fulfill Diagnostic Criteria and if they are Females

by Yazici, Y., Bernstein, H., Swearingen, C.
Published in Annals of the rheumatic diseases (01.06.2015)

Get full text

Journal Article

THU0302 Proposed Disease Activity Category Thresholds for Behcet's Syndrome Activity Scale (BSAS) Scores for a Potential “Treat to Target” Approach to Behcet's Syndrome

THU0302 Proposed Disease Activity Category Thresholds for Behcet's Syndrome Activity Scale (BSAS) Scores for a Potential “Treat to Target” Approach to Behcet's Syndrome

by Yazici, Y., Bernstein, H., Swearingen, C.
Published in Annals of the rheumatic diseases (01.06.2015)

Get full text

Journal Article

SAT0480 How many patients do we really need to enroll in randomized clinical trials of biologic agents for the treatment of rheumatoid arthritis? An analysis of published trials

SAT0480 How many patients do we really need to enroll in randomized clinical trials of biologic agents for the treatment of rheumatoid arthritis? An analysis of published trials

by Celik, S., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

SAT0586 Results from a 52 week randomised, double-blind, placebo-controlled, phase 2 study of a novel, wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment

SAT0586 Results from a 52 week randomised, double-blind, placebo-controlled, phase 2 study of a novel, wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment

by Yazici, Y., McAlindon, T., Gibofsky, A., Lane, N., Clauw, D., Swearingen, C., DiFrancesco, A., Tambiah, J., Hochberg, M.
Published in Annals of the rheumatic diseases (01.06.2018)

Get full text

Journal Article

Treatment of cyanide effluents by oxidation and adsorption in batch and column studies

Treatment of cyanide effluents by oxidation and adsorption in batch and column studies

by Yazıcı, E.Y., Deveci, H., Alp, İ.
Published in Journal of hazardous materials (30.07.2009)

Get full text

Journal Article

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database

by Sokka, T, Kautiainen, H, Pincus, T, Toloza, S, da Rocha Castelar Pinheiro, G, Lazovskis, J, Hetland, M L, Peets, T, Immonen, K, Maillefert, J F, Drosos, A A, Alten, R, Pohl, C, Rojkovich, B, Bresnihan, B, Minnock, P, Cazzato, M, Bombardieri, S, Rexhepi, S, Rexhepi, M, Andersone, D, Stropuviene, S, Huisman, M, Sierakowski, S, Karateev, D, Skakic, V, Naranjo, A, Baecklund, E, Henrohn, D, Gogus, F, Badsha, H, Mofti, A, Taylor, P, McClinton, C, Yazici, Y
Published in Annals of the rheumatic diseases (01.11.2009)

Get full text

Journal Article

OMERACT-OARSI ‘strict responders’ analysis from results of a randomized, double-blind, placebo-controlled phase 1 study of a novel, intra-articular, injectable, Wnt inhibitor (SM04690) in the treatment of osteoarthritis of the knee

OMERACT-OARSI ‘strict responders’ analysis from results of a randomized, double-blind, placebo-controlled phase 1 study of a novel, intra-articular, injectable, Wnt inhibitor (SM04690) in the treatment of osteoarthritis of the knee

by Yazici, Y, Tambiah, J, Swearingen, C.J, DiFrancesco, A, Strand, V
Published in Osteoarthritis and cartilage (01.04.2016)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[14]